AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20714379 — intervention group
Group type: COMPARATOR
Intervention: Control group (guaiphenesin treatment)
Number of subjects: 100
Study 17975955 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser with AH Plus cement
Number of subjects: 80
Study 17975955 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser with AH Plus cement
Number of subjects: 80
Study 17975955 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser with EndoREZ cement
Number of subjects: 80
Study 17975955 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser with EndoREZ cement
Number of subjects: 80
Study 17975955 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser treatment) with AH Plus cement
Number of subjects: 80
Study 17975955 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser treatment) with EndoREZ cement
Number of subjects: 80
Study 17314442 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% topical tea tree oil gel
Number of subjects: 60
Study 17314442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15036669 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 750mg daily
Number of subjects: 309
Study 15036669 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (Control)
Number of subjects: 309
Study 11271856 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscuit with synthetic beta-carotene
Number of subjects: 265
Study 11271856 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscuit with red palm oil
Number of subjects: 265
Study 11271856 — intervention group
Group type: COMPARATOR
Intervention: Placebo biscuit
Number of subjects: 265
Study 9179054 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 47
Study 9179054 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 47
Study 1304212 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% prednisolone acetate
Number of subjects: 20
Study 1304212 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dexamethasone
Number of subjects: 20
Study 1304212 — intervention group
Group type: COMPARATOR
Intervention: Untreated fellow-eyes
Number of subjects: 20
Study 3883441 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 28
Study 3883441 — intervention group
Group type: COMPARATOR
Intervention: Control (no indomethacin)
Number of subjects: 28
Study 30688558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1%
Number of subjects: 96
Study 30688558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3%
Number of subjects: 96
Study 30688558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 29991347 — intervention group
Group type: COMPARATOR
Intervention: Sertraline 50 mg/day
Number of subjects: 2011
Study 29991347 — intervention group
Group type: COMPARATOR
Intervention: Sertraline 100 mg/day
Number of subjects: 2011
Study 29991347 — intervention group
Group type: COMPARATOR
Intervention: Continue sertraline
Number of subjects: 2011
Study 29991347 — intervention group
Group type: EXPERIMENTAL
Intervention: Add mirtazapine
Number of subjects: 2011
Study 29991347 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to mirtazapine
Number of subjects: 2011
Study 26914134 — intervention group
Group type: COMPARATOR
Intervention: Methoxamine 2 mg alone (Group M)
Number of subjects: 160
Study 26914134 — intervention group
Group type: COMPARATOR
Intervention: Methoxamine 2 mg with atropine 0.1 mg (Group MA1)
Number of subjects: 160
Study 26914134 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine 2 mg with atropine 0.2 mg (Group MA2)
Number of subjects: 160
Study 26914134 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine 2 mg with atropine 0.3 mg (Group MA3)
Number of subjects: 160
Study 26914134 — intervention group
Group type: COMPARATOR
Intervention: All groups (M, MA1, MA2, MA3)
Number of subjects: 160
Study 24355994 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation (PNS) for 3 weeks
Number of subjects: 25
Study 24355994 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 25
Study 22799559 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate renal insufficiency (CKD with eGFR <60)
Number of subjects: 6209
Study 22799559 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants categorized by CKD status and BMI groups
Number of subjects: 6209
Study 20623289 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cc 1% Lignocaine at apical region (Group B)
Number of subjects: 386
Study 20623289 — intervention group
Group type: COMPARATOR
Intervention: No anaesthesia (Group A)
Number of subjects: 386
Study 20623289 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cc 1% Lignocaine at both bases (Group C)
Number of subjects: 386
Study 20623289 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cc at apex and 3 cc at both bases (Group D)
Number of subjects: 386
Study 17981854 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised in-laboratory time of 64 hours over 10 days (SD = 2.6)
Number of subjects: 35
Study 17981854 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific practice schedule
Number of subjects: 35
Study 16377604 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 279
Study 16377604 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 279
Study 12496753 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisimultaneous administration of midazolam (5 mg orally followed by 2 mg IV after 6 hours)
Number of subjects: 12
Study 12496753 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole administration
Number of subjects: 12
Study 12496753 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (individual midazolam doses, 1 week apart)
Number of subjects: 12
Study 9752816 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions (teleconference, small group workshops, newsletters)
Number of subjects: 4403
Study 9752816 — intervention group
Group type: COMPARATOR
Intervention: Media impacts (adverse news about CCBs)
Number of subjects: 4403
Study 9752816 — intervention group
Group type: COMPARATOR
Intervention: CCB or ACE inhibitor as first-line therapy
Number of subjects: 4403
Study 7657846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline 260 mg/day
Number of subjects: 68
Study 7657846 — intervention group
Group type: COMPARATOR
Intervention: Flecainide 200 mg/day
Number of subjects: 68
Study 7657846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline
Number of subjects: 68
Study 7657846 — intervention group
Group type: COMPARATOR
Intervention: Flecainide
Number of subjects: 68
Study 7657846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline and Flecainide
Number of subjects: 68
Study 2720134 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole 240 mg verapamil sustained-release tablet
Number of subjects: 12
Study 773086 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 100
Study 773086 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 100
Study 773086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31525490 — intervention group
Group type: EXPERIMENTAL
Intervention: Child care-center based lessons (18-week gross motor and 12-week nutrition) administered by trained child care staff
Number of subjects: 864
Study 31525490 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention for caregivers in addition to center-based lessons
Number of subjects: 864
Study 31525490 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 864
Study 28990161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided axillary vein cannulation
Number of subjects: 132
Study 28990161 — intervention group
Group type: COMPARATOR
Intervention: Landmark-guided subclavian vein cannulation
Number of subjects: 132
Study 26984901 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with Albendazole (ABZ) 15 mg/k/d for 10 days and Praziquantel (PZQ) 50 mg/k/d for 10 days
Number of subjects: 32
Study 26984901 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (ABZ) alone 15 mg/k/d for 10 days
Number of subjects: 32
Study 24717377 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 200
Study 24717377 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of treatment
Number of subjects: 200
Study 24717377 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy with sertraline
Number of subjects: 200
Study 23043965 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect moxibustion 2 times per week for 4 weeks (Treatment group A)
Number of subjects: 45
Study 23043965 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect moxibustion 3 times per week for 4 weeks (Treatment group B)
Number of subjects: 45
Study 23043965 — intervention group
Group type: COMPARATOR
Intervention: Current lifestyle maintenance (Control group)
Number of subjects: 45
Study 19704392 — intervention group
Group type: EXPERIMENTAL
Intervention: History of sexual abuse in the past year
Number of subjects: 665
Study 19704392 — intervention group
Group type: COMPARATOR
Intervention: No history of sexual abuse
Number of subjects: 665
Study 17469667 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-weight-bearing single-joint quadriceps exercise (SJNWBE)
Number of subjects: 45
Study 17469667 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing multiple-joint quadriceps exercise (MJWBE)
Number of subjects: 45
Study 17469667 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 45
Study 16036041 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone blockade (specific drug not mentioned, but refers to Aldactone and Eplerenone)
Number of subjects: 0
Study 16036041 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12915929 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous three‐lead orthogonal ECG monitoring in PTCA patients
Number of subjects: 55
Study 12915929 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous three‐lead orthogonal ECG monitoring in ACS patients
Number of subjects: 55
Study 12915929 — intervention group
Group type: COMPARATOR
Intervention: Standard 100 μV threshold
Number of subjects: 55
Study 10557001 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt restriction diet (5 grams of sodium chloride per day) with oral and written instructions from a clinical nutritionist and provision of low sodium bread (0.5%) during weeks 4-24.
Number of subjects: 39
Study 10557001 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt restriction diet (5 grams of sodium chloride per day).
Number of subjects: 39
Study 8739026 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice with quinidine sulfate (400 mg)
Number of subjects: 12
Study 8739026 — intervention group
Group type: COMPARATOR
Intervention: Water with quinidine sulfate (400 mg)
Number of subjects: 12
Study 1902054 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (Streptokinase or rt-PA)
Number of subjects: 395
Study 1902054 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 395
Study 1902054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 7132728 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 19
Study 7132728 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (400 mg) after placebo
Number of subjects: 19
Study 7132728 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg) after Cimetidine
Number of subjects: 19
Study 7132728 — intervention group
Group type: COMPARATOR
Intervention: Thyrotropin-releasing hormone (25 micrograms) after placebo or Met
Number of subjects: 19
Study 30898325 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT/TC/TXT
Number of subjects: 55
Study 30898325 — intervention group
Group type: COMPARATOR
Intervention: SG
Number of subjects: 55
Study 27046445 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabodenoson (200, 400, 800, 1,600, 2,400, or 3,200 μg)
Number of subjects: 60
Study 27046445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27046445 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabodenoson
Number of subjects: 60
Study 24861853 — intervention group
Group type: EXPERIMENTAL
Intervention: USL255 (topiramate) extended-release capsules, single doses ranging from 25-1,400 mg
Number of subjects: 0
Study 22594648 — intervention group
Group type: COMPARATOR
Intervention: Homeopathic remedy (Sulphur or Pulsatilla) at potencies of 6c, 12c, or 30c, presented in a randomized order over 3 sessions.
Number of subjects: 97
Study 19161631 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight‐bearing balance and strengthening exercises with cueing strategies for freezing of gait (intervention group)
Number of subjects: 230
Study 19161631 — intervention group
Group type: COMPARATOR
Intervention: Usual‐care control group
Number of subjects: 230
Study 17909382 — intervention group
Group type: EXPERIMENTAL
Intervention: Designed delays (DD) trial of nebulizer-to-inhaler conversion policy
Number of subjects: 104
Study 17909382 — intervention group
Group type: EXPERIMENTAL
Intervention: Designed delays (DD) trial of reduced restrictions on Cox-2 inhibitors
Number of subjects: 104
Study 17909382 — intervention group
Group type: EXPERIMENTAL
Intervention: Researchers' recollections of their degree of influence on decisions
Number of subjects: 104
Study 16330739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation tube (VT) treatment
Number of subjects: 113
Study 16330739 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (no ventilation tubes)
Number of subjects: 113
Study 11986409 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (metoprolol or carvedilol)
Number of subjects: 53
Study 11986409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 9455713 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine slow-release formulation with food
Number of subjects: 24
Study 9455713 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine slow-release formulation without food (12-hour fast)
Number of subjects: 24
Study 9455713 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine slow-release formulation (both conditions)
Number of subjects: 24
Study 7963067 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 79
Study 7963067 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 79
Study 3671253 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 21
Study 3671253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30617388 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:00.000 adrenaline
Number of subjects: 96
Study 30617388 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% prilocaine with felypressin 0.03 I.U. per ml
Number of subjects: 96
Study 29433613 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicated medication for schizophrenia or mood disorders along with usual prayer camp activities (prayers, chain restraints and fasting)
Number of subjects: 139
Study 29433613 — intervention group
Group type: COMPARATOR
Intervention: Prayer camp activities alone (no medication)
Number of subjects: 139
Study 27793431 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT intervention
Number of subjects: 152
Study 24717790 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol pMDI 2.25 micrograms
Number of subjects: 54
Study 24717790 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol pMDI 4.5 micrograms
Number of subjects: 54
Study 24717790 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol pMDI 9 micrograms
Number of subjects: 54
Study 24717790 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol dry powder inhaler 12 micrograms (active comparator)
Number of subjects: 54
Study 24717790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 23046709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 17β estradiol 3 mg/day for two months + 200 mg/day of micronized progesterone by vaginal route 14 days/month (E2+P)
Number of subjects: 86
Study 23046709 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous 17β estradiol gel 1.5 mg/day for three months + 200 mg/day of micronized progesterone by vaginal route 14 days/month (E2+P)
Number of subjects: 86
Study 23046709 — intervention group
Group type: COMPARATOR
Intervention: Intranasal 17β estradiol 3 mg/day for two months (E2)
Number of subjects: 86
Study 23046709 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous 17β estradiol gel 1.5 mg/day for three months (E2)
Number of subjects: 86
Study 19578221 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaferone LB
Number of subjects: 40
Study 19578221 — intervention group
Group type: COMPARATOR
Intervention: Standard program of intensive therapy
Number of subjects: 40
Study 17804681 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment to a clinical trial (no change in therapy)
Number of subjects: 1040
Study 15096911 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.65 g/kg)
Number of subjects: 34
Study 15096911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11241092 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg intravenous methylprednisolone during sternotomy and 30 mg/kg during initiation of cardiopulmonary bypass
Number of subjects: 90
Study 11241092 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg methylprednisolone at the same 2 times
Number of subjects: 90
Study 11241092 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution at the same 2 times
Number of subjects: 90
Study 9706371 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone 300 mg t.i.d.
Number of subjects: 17
Study 9706371 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone (various dosages from 60 mg to 300 mg t.i.d.)
Number of subjects: 17
Study 9706371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 9706371 — intervention group
Group type: COMPARATOR
Intervention: Piracetam 800 mg t.i.d.
Number of subjects: 17
Study 8311588 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous warm blood cardioplegia with systemic normothermia (≥ 35 degrees C)
Number of subjects: 1001
Study 8311588 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cold oxygenated crystalloid cardioplegia and moderate systemic hypothermia (≤ 28 degrees C)
Number of subjects: 1001
Study 3257805 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation combined with voluntary muscle contractions
Number of subjects: 23
Study 3257805 — intervention group
Group type: COMPARATOR
Intervention: Voluntary muscle contractions only (Control)
Number of subjects: 23
Study 1396833 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of full length unglycosylated single‐chain‐urokinase plasminogen activator (saruplase)
Number of subjects: 401
Study 1396833 — intervention group
Group type: COMPARATOR
Intervention: 1.5 million IU of streptokinase delivered over a 60 min period
Number of subjects: 401
Study 277069 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 per cent urea peroxide solution
Number of subjects: 60
Study 277069 — intervention group
Group type: COMPARATOR
Intervention: Normal oral hygiene instructions
Number of subjects: 60
Study 31029863 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin intervention
Number of subjects: 75
Study 31029863 — intervention group
Group type: COMPARATOR
Intervention: Control group (MTHFR 677CC genotype)
Number of subjects: 75
Study 30688082 — intervention group
Group type: EXPERIMENTAL
Intervention: Early limited‐volume DHM supplementation
Number of subjects: 60
Study 30688082 — intervention group
Group type: COMPARATOR
Intervention: Exclusive breastfeeding
Number of subjects: 60
Study 28606098 — intervention group
Group type: EXPERIMENTAL
Intervention: PedsQL Sickle Cell Disease Module
Number of subjects: 0
Study 25550288 — intervention group
Group type: EXPERIMENTAL
Intervention: Loozit() group programme with additional therapeutic contact (telephone coaching, SMS, emails)
Number of subjects: 151
Study 25550288 — intervention group
Group type: COMPARATOR
Intervention: Loozit() group programme without additional therapeutic contact
Number of subjects: 151
Study 23438496 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-g whey supplement
Number of subjects: 10
Study 23438496 — intervention group
Group type: COMPARATOR
Intervention: 45-g maltodextrin control
Number of subjects: 10
Study 23438496 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary urea
Number of subjects: 10
Study 20861415 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion based on lean body weight (LBW)
Number of subjects: 60
Study 20861415 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion based on total body weight (TBW)
Number of subjects: 60
Study 20861415 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving propofol infusion based on total body weight (TBW)
Number of subjects: 60
Study 19777735 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (Valdoxan®)
Number of subjects: 0
Study 16516954 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol dose
Number of subjects: 24
Study 16516954 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg alcohol dose
Number of subjects: 24
Study 16516954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 14739053 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (repaglinide plus pioglitazone)
Number of subjects: 246
Study 14739053 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide
Number of subjects: 246
Study 14739053 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 246
Study 11691689 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 53
Study 9140529 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread baked with alpha-amylase and hemicellulase
Number of subjects: 17
Study 9140529 — intervention group
Group type: COMPARATOR
Intervention: Bread baked without enzymes (control)
Number of subjects: 17